{"prompt": "['SUMMARY OF CHANGES', 'Longitudinal Quality of Life Study among Participants with AIDS-Associated Kaposi', 'Sarcoma at Bugando Medical Centre, in Mwanza, Tanzania', 'Version 2.0', 'NCI Protocol #: AMC-S007', 'Local Protocol #: AMC-S007', 'NCI Version Date: 20MAR2018', 'Protocol Date: 20MAR2018', '#', 'Section', 'Comments', '1.', 'Global', 'Changed from:', 'Version 1.0, 21NOV2017', 'NCI Version 21NOV2017', 'Changed to:', 'Version 2.0, 20MAR2018', 'NCI Version 20MAR2018', '2.', 'Global', 'Changed from:', 'Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)', 'Changed to:', 'Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)', '3.', '6.3.3', 'Changed from:', 'Death due to progressive disease should be reported as Grade 5 \"Neoplasms benign,', 'malignant and unspecified (incl cysts and polyps) - Other (Progressive Disease)\" under', 'the system organ class (SOC) of the same name. Evidence that the death was a', 'manifestation of underlying disease (e.g., radiological changes suggesting tumor growth or', 'progression: clinical deterioration associated with a disease process) should be submitted.', 'Changed to:', 'Death due to progressive disease should be reported as Grade 5 \"General disorders and', 'administration site conditions - Disease Progression\". Evidence that the death was', 'a', 'manifestation of underlying disease (e.g., radiological changes suggesting tumor growth or', 'progression: clinical deterioration associated with a disease process) should be submitted.', '4.', '6.3.4', 'Changed from:', 'Pregnancy reporting and outcomes will be documented by completion of the appropriate', 'CRFs, including the Adverse Event form.', 'Changed to:', 'Pregnancy reporting and outcomes will be documented by completion of the appropriate', 'CRFs, including the Adverse Event form, using the appropriate term in the system organ', 'class (SOC) for Pregnancy, puerperium and perinatal conditions.', 'AMC-S007 (Version 2.0) 20MAR2018', 'i', 'NCI Version Date 20MAR2018']['#', 'Section', 'Comments', '5.', '8.1.5', 'Changed from:', 'Complete blood cell counts with differentials and platelets, and serum liver/renal function', 'analysis. This should include the following: albumin, alkaline phosphatase, total bilirubin,', 'bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus, potassium,', 'total protein, SGOT [AST], SGPT [ALT], sodium.', 'Changed to:', 'Complete blood cell counts with differentials and platelets, and serum liver/renal function', 'analysis. This should include the following: total and direct bilirubin, creatinine, SGOT', '[AST], SGPT [ALT].', '6.', 'Appendix I', 'Changed from:', \"Instructions: In the event that the participant's condition is deteriorating, laboratory\", 'evaluations should be repeated within 24 hours before initiation of the next cycle of therapy.', 'Footnote a: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium,', 'chloride, creatinine, glucose, LDH, phosphorus, potassium, total protein, SGOT [AST],', 'SGPT [ALT], sodium.', 'Changed to:', \"Instructions: If the participant's condition is deteriorating, laboratory evaluations should be\", 'repeated within 24 hours before initiation of the next cycle of therapy.', 'Footnote a: Total and direct bilirubin, creatinine, SGOT [AST], SGPT [ALT].', 'AMC-S007 (Version 2.0) 20MAR2018', 'ii', 'NCI Version Date 20MAR2018']['AMC', 'AIDS Malignancy', 'Consortium', 'AIDS MALIGNANCY CONSORTIUM', 'AMC PROTOCOL #S007:', 'Longitudinal Quality of Life Study Among Participants with', 'AIDS-Associated Kaposi Sarcoma at Bugando Medical Centre, in', 'Mwanza, Tanzania', 'A Trial of the AIDS Malignancy Consortium (AMC)', 'Sponsored by:', 'National Cancer Institute', 'Office of HIV and AIDS Malignancy (OHAM)', 'NCT Registration Number:', 'TBD', 'Regulatory Status:', 'Subject to Review by the BMC/CUHAS Research Ethics', 'Committee and the Tanzanian National Institute for', 'Medical Research (NIMR)', 'Commercially Available', 'Bleomycin (NSC 125066)', 'Agents:', 'Vincristine sulfate (NSC 67574)', 'Protocol Chair:', 'Kristin Schroeder, MD, MPH', 'Protocol Co-Chair:', 'Nestory Masalu, MD, MMed', 'Version 2.0', '20 March 2018', 'NCI Version 20 March 2018', 'AMC-S007 (Version 2.0) 20MAR2018', '1', 'NCI Version Date 20MAR2018']['AMC PROTOCOL SIGNATURE PAGE', 'I, Nestory Masalu, Principal Investigator at site Bugando Medical Centre agree to conduct and', 'follow this protocol: AMC Protocol #S007 - Longitudinal Quality of Life Study Among', 'Participants with AIDS-Associated Kaposi Sarcoma at Bugando Medical Centre, in', 'Mwanza, Tanzania (Version 2.0, 20MAR2018), as written according to AMC, NCI, and', 'National Institute for Medical Research (NIMR) guidelines. I understand that no deviations from', 'the protocol eligibility criteria or waivers for protocol deviations will be permitted.', 'Signature', 'Date (dd/mmm/yyyy)', 'AMC-S007 (Version 2.0) 20MAR2018', '2', 'NCI Version Date 20MAR2018']", "completion": ""}